Recent data from JPM2026 shows that China has surpassed the United States in key biotech activity measures—topping the US in deal value, clinical trial volume, and the pace of licensing, especially in cell and gene therapies. This signals a major shift in global drug discovery: China is no longer just a large market, but a leading source of next‑generation therapies and capital‑rich collaborations.
What the Data Shows
- In 2025–early 2026, China was involved in more biotech deal value than the US, including major licensing, partnerships, and M&A.
- Clinical trial activity in China now exceeds that in the US, with more trials launched each year in oncology, immunology, and rare diseases.
- Cell and gene therapy assets originating in China are increasingly being licensed by global pharma, often at high upfronts and milestone‑based structures.
Why China Is Gaining Ground
- Strong national support for innovation, coupled with large‑scale clinical and genomic data, is accelerating R&D timelines.
- Chinese companies are investing heavily in AI‑driven drug discovery, advanced biologics, and cell‑therapy platforms.
- Collaborations with global firms—often structured through Hong Kong and other hubs—are making it easier to bring Chinese‑born assets to the world market.
Strategic Impact for 2026
- Global pharma can no longer rely only on US‑ or Europe‑born innovation; many of the most promising assets now come from China.
- Chinese biotech companies are gaining stronger negotiating power, as international demand for AI‑driven, cell‑ and gene‑based therapies continues to grow.
- Deals increasingly include access to Chinese data platforms, AI tools, and domestic‑market rights, making them more complex—but also more valuable.
Risks and Balance
- Regulatory, geopolitical, and IP issues will shape how widely Chinese‑born therapies are accepted worldwide.
- Not all high‑profile assets will succeed; clinical risk, pricing pressure, and reimbursement hurdles remain.
Executive Takeaway
China’s rise to the top in biotech deal value and trials suggests a new era in which Chinese innovation drives much of global drug discovery. The shift is particularly clear in cell and gene therapy, where Chinese‑licensed programs are becoming central to global pipelines. For 2026 and beyond, this trend positions China not just as a large market, but as a leading engine of biotech advancement worldwide.
By